Filtered By:
Condition: Heart Attack
Drug: Metformin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 151 results found since Jan 2013.

Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database
ConclusionsTreatment with SGLT2 inhibitors or GLP-1 receptor agonists might reduce non-fatal stroke/TIA in persons with newly diagnosed type 2 diabetes.
Source: Acta Diabetologica - August 6, 2022 Category: Endocrinology Source Type: research

Case–control study of oral glucose‐lowering drugs in combination with long‐acting insulin and the risks of incident myocardial infarction and incident stroke
ConclusionsSulfonylureas in combination with long‐acting insulin may increase the risk of MI compared with the use of insulin alone. Metformin may be an important cardiovascular disease prevention therapy for patients on insulin therapy. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - November 8, 2015 Category: Drugs & Pharmacology Authors: James S. Floyd, Kerri L. Wiggins, Mark Christiansen, Sascha Dublin, William T. Longstreth, Nicholas L. Smith, Barbara McKnight, Susan R. Heckbert, Noel S. Weiss, Bruce M. Psaty Tags: Original Report Source Type: research

Case–control study of second‐line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke
ABSTRACT We conducted a population‐based case–control study to assess the myocardial infarction (MI) and stroke risks associated with sulfonylureas and insulin when used in combination with metformin. Cases had type 2 diabetes and used metformin + insulin or metformin + sulfonylureas at the time of a first MI or first stroke from 1995–2010; controls used the same treatment combinations and were randomly sampled from the same population. MI and stroke diagnoses and potential confounders were validated by medical record reviews. Compared with metformin + sulfonylurea, metformin + insulin was associated ...
Source: Diabetes, Obesity and Metabolism - July 14, 2015 Category: Endocrinology Authors: James S. Floyd, Kerri L. Wiggins, Colleen M. Sitlani, James H. Flory, Sascha Dublin, Nicholas L. Smith, Susan R. Heckbert, Bruce M. Psaty Tags: Research Letter Source Type: research

Metformin associated with better cardiovascular outcomes than other glycaemic therapies
Context A question exists as to whether the outcome of glycaemic treatment of diabetes varies with the agent used; speculation surrounds whether metformin might be preferable to other treatments. Methods Ghotbi and colleagues performed an epidemiological analysis of 8192 obese patients with diabetes at increased cardiovascular risk participating in the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Mortality and a combined cardiovascular outcome of non-fatal myocardial infarction, non-fatal stroke, resuscitation after cardiac arrest or cardiovascular death were compared among those receiving one of the following interv...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Bloomgarden, Z. T. Tags: Smoking and tobacco, Epidemiologic studies, Drugs: cardiovascular system, Heart failure, Stroke, Hypertension, Diet, Obesity (nutrition), Ischaemic heart disease, Diabetes, Health education, Smoking Therapeutics Source Type: research

Antibiotic use linked to increased risk of heart attack and stroke in women
Risk is greatest for older women who take antibiotics for more than two months Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Cardio risk raised in people using long-acting bronchodilators Recurrent stroke more likely at very low BP Rising use of antithrombotics linked to subdural haematoma Adding insulin to metformin linked to higher mortality
Source: OnMedica Latest News - May 27, 2019 Category: UK Health Source Type: news

Could exercise be as effective as medication?
Conclusion The researchers found that there are very few trials that directly compare exercise with drug therapy for any condition. They were only able to find enough trials to be able to analyse results for four major conditions. They found that exercise reduced death rates for people after a stroke (although this analysis has limitations and should be interpreted cautiously), and that drug therapy with diuretics improved death rates for people with heart failure. They did not find any difference between exercise and drug therapy for death rates after a heart attack or in people with pre-diabetes. There were several limit...
Source: NHS News Feed - October 2, 2013 Category: Consumer Health News Tags: Lifestyle/exercise Heart/lungs Medication Source Type: news

People With Diabetes Are More Vulnerable to Heart Disease. How to Reduce the Risk
If you’ve been diagnosed with diabetes, know that you’ve got plenty of company. The American Diabetes Association (ADA) reports that in 2019, the most recent year for which data is available, 37.3 million adults in the U.S.—about 11.3% of the population—had the chronic condition, and that number continues to grow. Type 1 diabetes develops when the body isn’t able to produce insulin, and Type 2 occurs when the body doesn’t use insulin correctly. Type 2 is the most common form of diabetes, and when it’s uncontrolled, a person’s blood sugar can jump to dangerous levels that requ...
Source: TIME: Health - July 20, 2022 Category: Consumer Health News Authors: Elaine K. Howley Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news

Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
CONCLUSIONS: Findings from both standard and network meta-analyses of moderate- to high-certainty evidence suggest that GLP-1RA and SGLT2i are likely to reduce the risk of CVD mortality and all-cause mortality in people with established CVD; high-certainty evidence demonstrates that treatment with SGLT2i reduce the risk of hospitalisation for HF, while moderate-certainty evidence likely supports the use of GLP-1RA to reduce fatal and non-fatal stroke. Future studies conducted in the non-diabetic CVD population will reveal the mechanisms behind how these agents improve clinical outcomes irrespective of their glucose-lowerin...
Source: Cochrane Database of Systematic Reviews - October 25, 2021 Category: General Medicine Authors: Takayoshi Kanie Atsushi Mizuno Yoshimitsu Takaoka Takahiro Suzuki Daisuke Yoneoka Yuri Nishikawa Wilson Wai San Tam Jakub Morze Andrzej Rynkiewicz Yiqiao Xin Olivia Wu Rui Providencia Joey Sw Kwong Source Type: research

Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study
CONCLUSION: As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin.PRIMARY FUNDING SOURCE: Brigham and Women's Hospital and Harvard Medical School.PMID:35605236 | DOI:10.7326/M21-4012
Source: Annals of Internal Medicine - May 23, 2022 Category: Internal Medicine Authors: HoJin Shin Sebastian Schneeweiss Robert J Glynn Elisabetta Patorno Source Type: research

Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years’ follow‐up
ConclusionsThe cumulative incidence of cardiovascular disease and myocardial infarction increased with number of previous events and presence of hyperglycaemia and hypertension and decreased with pharmacological treatment of diabetes. A higher number of previous stroke events increased the cumulative incidence of stroke but no protective effect of pharmacological treatment was observed.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - June 1, 2014 Category: Endocrinology Authors: S.P.O. Jansson, D.K.G. Andersson, K. Svärdsudd Tags: Research Article Source Type: research

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Abstract During the last decade, the armamentarium for glucose-lowering drugs has increased enormously by the development of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors, allowing individualization of antidiabetic therapy for patients with type 2 diabetes (T2DM). Some combinations can now be used without an increased risk for severe hypoglycemia and weight gain. Following a request of the US Food and Drug Administration, many large cardiovascular (CV) outcome studies have been performed in patients with longstanding disease and established CV disease. In the majority of CV outcome studies, CV ris...
Source: Clinical Therapeutics - May 18, 2016 Category: Drugs & Pharmacology Authors: Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH Tags: Clin Ther Source Type: research

Comparative cardiovascular risks of dipeptidyl peptidase ‐4 inhibitors with other 2nd and 3rd line antidiabetic drugs in patients with type 2 diabetes
ConclusionsDPP4i as 2nd and 3rd add‐on treatment provided cardiovascular benefits and posed no increased risks for heart failure, hypoglycemia and death.
Source: British Journal of Clinical Pharmacology - January 21, 2017 Category: Drugs & Pharmacology Authors: Huang ‐Tz Ou, Kai‐Cheng Chang, Chung‐Yi Li, Jin‐Shang Wu Tags: DRUG SAFETY Source Type: research